Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract develo… Read more
Lonza Group AG (LZAGY) - Net Assets
Latest net assets as of December 2025: $9.19 Billion USD
Based on the latest financial reports, Lonza Group AG (LZAGY) has net assets worth $9.19 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.97 Billion) and total liabilities ($9.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.19 Billion |
| % of Total Assets | 48.44% |
| Annual Growth Rate | 9.82% |
| 5-Year Change | -6.47% |
| 10-Year Change | 290.11% |
| Growth Volatility | 35.59 |
Lonza Group AG - Net Assets Trend (2004–2025)
This chart illustrates how Lonza Group AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lonza Group AG (2004–2025)
The table below shows the annual net assets of Lonza Group AG from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.19 Billion | -2.14% |
| 2024-12-31 | $9.39 Billion | -1.30% |
| 2023-12-31 | $9.51 Billion | -10.81% |
| 2022-12-31 | $10.66 Billion | +8.57% |
| 2021-12-31 | $9.82 Billion | +42.69% |
| 2020-12-31 | $6.88 Billion | +4.86% |
| 2019-12-31 | $6.57 Billion | +4.37% |
| 2018-12-31 | $6.29 Billion | +1.76% |
| 2017-12-31 | $6.18 Billion | +162.46% |
| 2016-12-31 | $2.35 Billion | +10.30% |
| 2015-12-31 | $2.13 Billion | +0.23% |
| 2014-12-31 | $2.13 Billion | +0.19% |
| 2013-12-31 | $2.13 Billion | -11.64% |
| 2012-12-31 | $2.41 Billion | +2.12% |
| 2011-12-31 | $2.36 Billion | -1.30% |
| 2010-12-31 | $2.39 Billion | -0.08% |
| 2009-12-31 | $2.39 Billion | +33.54% |
| 2008-12-31 | $1.79 Billion | -1.05% |
| 2007-12-31 | $1.81 Billion | +12.51% |
| 2006-12-31 | $1.61 Billion | +7.85% |
| 2005-12-31 | $1.49 Billion | +15.95% |
| 2004-12-31 | $1.28 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lonza Group AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 611.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $9.92 Billion | 108.57% |
| Common Stock | $70.00 Million | 0.77% |
| Other Comprehensive Income | $-1.81 Billion | -19.77% |
| Other Components | $953.05 Million | 10.43% |
| Total Equity | $9.13 Billion | 100.00% |
Lonza Group AG Competitors by Market Cap
The table below lists competitors of Lonza Group AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GLOBALFOUNDR. INC. DL-02
F:76J
|
$4.11 Billion |
|
Rational AG
LSE:0FRJ
|
$4.11 Billion |
|
ATGPF
PINK:ATGPF
|
$4.11 Billion |
|
Grupo Bimbo S.A.B. De C.V.
PINK:GRBMF
|
$4.11 Billion |
|
Chailease Holding Co Ltd
TW:5871
|
$4.11 Billion |
|
Orla Mining Ltd
NYSE MKT:ORLA
|
$4.11 Billion |
|
Frontline Ltd
NYSE:FRO
|
$4.11 Billion |
|
China Greatwall Computer Shenzhen Co Ltd
SHE:000066
|
$4.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lonza Group AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,328,000,000 to 9,134,000,000, a change of -194,000,000 (-2.1%).
- Net income of 949,000,000 contributed positively to equity growth.
- Dividend payments of 267,412,016 reduced retained earnings.
- Share repurchases of 518,000,000 reduced equity.
- New share issuances of 11,000,000 increased equity.
- Other comprehensive income decreased equity by 531,049,352.
- Other factors increased equity by 162,461,368.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $949.00 Million | +10.39% |
| Dividends Paid | $267.41 Million | -2.93% |
| Share Repurchases | $518.00 Million | -5.67% |
| Share Issuances | $11.00 Million | +0.12% |
| Other Comprehensive Income | $-531.05 Million | -5.81% |
| Other Changes | $162.46 Million | +1.78% |
| Total Change | $- | -2.08% |
Book Value vs Market Value Analysis
This analysis compares Lonza Group AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.38x to 4.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $2.51 | $58.74 | x |
| 2005-12-31 | $2.77 | $58.74 | x |
| 2006-12-31 | $2.72 | $58.74 | x |
| 2007-12-31 | $3.17 | $58.74 | x |
| 2008-12-31 | $3.14 | $58.74 | x |
| 2009-12-31 | $4.21 | $58.74 | x |
| 2010-12-31 | $4.20 | $58.74 | x |
| 2011-12-31 | $4.21 | $58.74 | x |
| 2012-12-31 | $4.29 | $58.74 | x |
| 2013-12-31 | $4.08 | $58.74 | x |
| 2014-12-31 | $4.08 | $58.74 | x |
| 2015-12-31 | $4.05 | $58.74 | x |
| 2016-12-31 | $4.45 | $58.74 | x |
| 2017-12-31 | $8.96 | $58.74 | x |
| 2018-12-31 | $8.32 | $58.74 | x |
| 2019-12-31 | $8.71 | $58.74 | x |
| 2020-12-31 | $9.12 | $58.74 | x |
| 2021-12-31 | $13.09 | $58.74 | x |
| 2022-12-31 | $14.25 | $58.74 | x |
| 2023-12-31 | $12.83 | $58.74 | x |
| 2024-12-31 | $13.08 | $58.74 | x |
| 2025-12-31 | $13.00 | $58.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lonza Group AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.39%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.53%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 2.08x
- Recent ROE (10.39%) is below the historical average (11.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 10.74% | 6.32% | 0.65x | 2.60x | $9.50 Million |
| 2005 | 12.62% | 7.46% | 0.58x | 2.91x | $39.00 Million |
| 2006 | 13.81% | 9.72% | 0.58x | 2.43x | $61.30 Million |
| 2007 | 16.65% | 10.49% | 0.58x | 2.74x | $120.20 Million |
| 2008 | 23.42% | 14.27% | 0.60x | 2.76x | $240.10 Million |
| 2009 | 6.84% | 5.91% | 0.54x | 2.13x | $-73.50 Million |
| 2010 | 11.90% | 10.60% | 0.56x | 2.00x | $45.30 Million |
| 2011 | 6.53% | 5.72% | 0.38x | 2.98x | $-81.70 Million |
| 2012 | 7.56% | 4.64% | 0.55x | 2.95x | $-58.70 Million |
| 2013 | 4.09% | 2.43% | 0.56x | 3.00x | $-125.60 Million |
| 2014 | 11.13% | 6.51% | 0.57x | 3.02x | $24.00 Million |
| 2015 | 12.97% | 7.28% | 0.61x | 2.93x | $63.50 Million |
| 2016 | 12.78% | 7.28% | 0.61x | 2.90x | $65.50 Million |
| 2017 | 11.84% | 15.96% | 0.33x | 2.26x | $112.70 Million |
| 2018 | 8.99% | 10.09% | 0.40x | 2.24x | $-62.80 Million |
| 2019 | 9.93% | 15.33% | 0.30x | 2.13x | $-4.40 Million |
| 2020 | 12.75% | 19.28% | 0.31x | 2.15x | $187.50 Million |
| 2021 | 30.19% | 54.43% | 0.33x | 1.69x | $1.97 Billion |
| 2022 | 11.47% | 19.52% | 0.36x | 1.64x | $155.30 Million |
| 2023 | 6.92% | 9.74% | 0.40x | 1.78x | $-291.20 Million |
| 2024 | 6.82% | 9.67% | 0.33x | 2.12x | $-296.80 Million |
| 2025 | 10.39% | 14.53% | 0.34x | 2.08x | $35.60 Million |
Industry Comparison
This section compares Lonza Group AG's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lonza Group AG (LZAGY) | $9.19 Billion | 10.74% | 1.06x | $4.11 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |